Scientific Advisory Board
Dr. Kasten is a graduate of Miami University (Oxford Ohio), BA Chemistry 1967, and the Ohio State University College of Medicine MD 1971. His residency was served at the University of Miami, Florida and fellowships at the National Institutes of Health Clinical Center and National Cancer Institute, Bethesda, Maryland. He is a Diplomat of the American Board of Pathology with Certification in Anatomic and Clinical Pathology with sub-specialty certification in Medical Microbiology.
Dr. Kasten served eight years, 1996-2004 at Quest Diagnostics Inc. [NYSE-DGX] where he was Chief Laboratory Officer; Vice-President of Business Development for Science and Medicine, and Vice-President of Medical Affairs of a Quest Diagnostics wholly owned subsidiary, MedPlus Inc. He joined SIGA Technologies, Inc. [NASDAQ-SIGA] as a member of the Board of Directors in May 2003, and accepted appointment as SIGA’s Chief Executive Officer in July of 2004, serving through April 2006.
He was elected Chairman of the Board of Cleveland Bio Labs Inc. [NASDAQ-CBLI] in July 2006 and was elected to the Board of Directors of Enzo Biochem Inc. [NYSE-ENZ] in January 2008.
Dr. Kasten has been a Scientific Advisor to GeneLink Inc. [GNLK.OB] since 1999. He joined GeneLink’s Board of Directors and was elected Executive Chairman in April 2007.
Dr. Robert Ricciardi is a Professor of Microbiology at the University of Pennsylvania, where he is a Graduate Group Chairman. He received his Ph.D. from the University of Illinois at Urbana. He was a Postdoctoral Fellow at Brandeis University and Harvard Medical School in the Department of Biological Chemistry where he was awarded Fellowships by the American Cancer Society, National Institutes of Health and the Charles A. King Trust. He developed one of the first genomic technologies, which was used widely to discover and map many hundreds of genes by identifying the proteins they encode. Most of Dr. Ricciardi’s research has centered on understanding basic mechanisms of cancer. He identified one of the first gene activators from a virus that can make cells cancerous by enabling them to escape the immune system. These studies, in turn, disclosed a key mechanism that modulates NF-kappa-B, the master regulator of the immune system. Dr. Riciardi has also developed and received patents on recombinant delivery vectors for potential use as vaccines and gene therapy. In addition, Dr. Ricciardi discovered new replication proteins from human viruses that cause cancer (KSHV) and possibly chronic fatigue (HHV-6). He is applying a rapid mechanistic assay he developed (US Patent) that is being used to screen tens of thousands of compounds from chemical libraries in order to discover therapeutics that will inhibit these and other disease related human viruses. Dr. Ricciardi has served as a consultant to Children’s Hospital of Philadelphia, Smith Kline Pharmaceuticals, the NIH, and was awarded a NATO Visiting Professorship at Ferrara Medical School and has been an invitational speaker at numerous international scientific meetings and universities. He has authored 93 publications.
Dr. Cannon received his A.B. in Chemistry from Harvard College and both a M.A. in Medical Sciences and a Ph.D in Biochemistry from Boston University. He was awarded pre- and postdoctoral fellowships from the National Institutes of Health. His career includes researcher, faculty member (Biochemistry and Pathology) and clinical laboratory director. He has been on the faculty at the Medical Schools at the University of Hawaii, University of Arkansas, and Marshall University where he has lectured to medical, graduate, nursing and allied health students and was director of the Pathology residency program at Marshall University. He has directed laboratories and performed research at the Boston Biomedical Research Institute, the University of Arkansas for Medical Sciences, the Little Rock, Arkansas VAMC, the Bethesda Hospitals in Cincinnati and Marshall University School of Medicine.
Dr. Cannon has also served as Laboratory Director in Forensic Toxicology, National Manager of Operations Excellence and National Manager of Special Projects in Business Ventures at Quest Diagnostics Inc. His main interests are in undergraduate teaching, clinical laboratory medicine, quality assurance and standardization, laboratory management, nutraceuticals, toxicology and forensic sciences. He has over 130 publications and book chapters, and is an active member of the American Association for Clinical Chemistry, the Association of Clinical Scientists and the National Academy of Clinical Biochemistry.
Dr. Cannon has recently taught undergraduate Chemistry at the University of Tampa to science majors, allied health students and non science majors. He established curricula for nursing students and developed a B.S. program in Forensic Sciences. He is currently a Professor of Chemistry at Florida Southern College in Lakeland, Florida.
Dr. Harrison serves as the Director of Clinical Pathology for Geisinger Medical Laboratories. He is also the Director of the Geisinger Lewistown Laboratory and the Proven Diagnostics laboratory in Bethlehem. In addition, Dr. Harrison is the Central Pennsylvania State Commissioner for the Laboratory Accreditation program, College of American Pathologists, and is a member of the Clinical Pathology Resource Committee of that College.
Dr. Harrison is a Clinical Pathologist and Medical Geneticist with 20 years of practice experience in all areas of clinical laboratory services, and subspecialty interests in genetics, clinical biochemistry, hematology and immunology. His research has focused on clinical and diagnostic applications of molecular genetic and proteomic techniques. As a faculty member at the University of Chicago Pritzker School of Medicine from 1984 to 1992, Dr. Harrison authored 80 publications and abstracts, and received several OMIM/Genome Data Base citations for genetic discoveries achieved through proteomics research.
Dr. Harrison was awarded a Bachelor of Science, with High Honors and Distinction Biochemistry by the University of Illinois at Urbana. He earned his M.D. and Ph.D. in Biochemical Genetics from the University of Illinois Medical School at Chicago. Following an Internship in Internal Medicine at the University of Illinois Hospital he completed a residency in Clinical Pathology and Laboratory Medicine at Northwestern University Medical School, with subsequent postdoctoral studies at Argonne National Laboratory prior to joining the clinical pathology faculty at the University of Chicago.
Dr. Kagan is Board Certified in Clinical Pathology, Nuclear Medicine and Hyperbaric Medicine. He received his medical degree from Georgetown University School of Medicine. His postgraduate medical education included a medical internship at the University of California San Francisco and residency training programs in Pathology and Nuclear Medicine at the National Institute of Health. Dr. Kagan is once again on the cutting edge of science as the Medical Director of BodyView, the first full body scanning facility to offer a programmic approach to healthcare. Prior to opening the first outpatient MRI center in Florida, Dr. Kagan was the Medical Director of Nuclear Medicine at Holy Cross Hospital in Fort Lauderdale and Clinical Assistant Professor of Radiology at the University of Miami.
Dr. Mittiga is a Diplomat of the American Board of Pediatrics. She received her medical degree from Case Western Reserve University, College of Medicine, served her residency at the University of Pittsburgh Children’s Hospital, and her fellowship at the Cincinnati Children’s Hospital Medical Center. Dr. Mittiga has an active pediatric private practice in Cincinnati, Ohio emphasizing pediatric wellness and child and adolescent nutrition.
Ms. Palazzolo has 13 years of experience designing, implementing and managing research studies and 10 years in conducting data analysis. Her work has been concentrated in both social sciences and medical research. Most recently she has undertaken a new area, network analysis. She is currently working with GeneLink to determine the effects of several newly developed products. She is a full time employee at Cincinnati Children’s Hospital Medical Center (CCHMC) in the James M. Anderson Center for Health Care Excellence where she is piloting new technology solutions to enable reliable population management for patients with chronic conditions. In addition she is part of a team of researchers from the Massachusetts Institute of Technology and CCHMC studying the development of health care providers’ communication networks to determine what factors predict perfect care. This research, the first of its kind, is being applied at CCHMC in teams caring for patients with chronic conditions. She graduated in 1999 from the University of Cincinnati with her Master’s of Science degree.
James W. Simpkins received his Ph.D. degree under the mentorship of the pioneering neuroendocrinologist, Joseph Meites at Michigan State University in 1977. He then joined the University of Florida where he rose through the academic ranks to a full professorship in 1986. At the University of Florida, he was the founding director of the Center for the Neurobiology of Aging, served as Chair of two departments and was appointed the Frank Duckworth Professor of Drug Discovery in 1996. In 2000, he became the Professor and Chair of the Department of Pharmacology & Neuroscience and Founding Director of the Institute for Aging and Alzheimer’s Disease Research at the University of North Texas Health Science Center at Fort Worth.
The author of more than 326 publications, his research has focus on the discovery of novel compounds for the treatment of age-related brain disorders, with a particular focus on Alzheimer’s disease and stroke. Among his discoveries are the first report of an animal model of menopausal hot flushes, the first report of estrogen neuroprotection, the first report that this potent action of estrogens is not mediated by any of the known estrogen receptors, the first description of the molecular requirements for neuroprotection by estrogens, the discovery that mitochondria are a site of estrogen neuroprotection, the discovery of a novel redox cycle of estrogens that is involved in its potent neuroprotection, and the discovery of Alzheimer’s neuropathology soon after an experimental cerebral ischemic event, an effect that is ameliorated be estrogen treatment.
Dr. Heinrich has joined Genelink as Director of Genomics. Stefanie Heinrich has a Diploma in Biochemistry from the department of human genetics at the Ruhr University Bochum, Germany. She received her Ph.D at the Dr.-von-Haunerschen children’s hospital in Munich, Germany, in the department of pneumology. Afterwards she worked as a researcher at the department of human genetics at the Justus-Liebig University in Giessen, Germany.